Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 83-88

John Wiley & Sons Inc

Access to resources Recommend Favorite

Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment

By  

Current Drug Targets, Vol. 14, Iss. 12, 2013-11 ,pp. : 1385-1391

Bentham Science Publishers

Access to resources Recommend Favorite

Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans

By  

Drug Metabolism Letters, Vol. 9, Iss. 1, 2015-04 ,pp. : 28-47

Bentham Science Publishers

Access to resources Recommend Favorite

Investigational Janus kinase inhibitors

By Tam Constantine S  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 687-699

Informa Healthcare

Access to resources Recommend Favorite

Tofacitinib

By  

Drugs in R&D, Vol. 10, Iss. 4, 2010-11 ,pp. : 271-284

Adis International

Access to resources Recommend Favorite